HIV VACCINE DESIGN AND DEVELOPMENT TEAM ? WYETH

HIV 疫苗设计和开发团队？

• 批准号: 7562306
• 负责人: Preston A Marx
• 金额: $ 7.16万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7562306
• 关键词: Animals; Antigens; Attenuated; Blood specimen; Body Temperature; Computer Retrieval of Information on Scientific Projects Database; DNA Vaccines; Development; Disease; Funding; Grant; Human; Immune response; Immunologic Monitoring; Institution; Macaca mulatta; Modeling; Monkeys; Pathogenesis; Recombinants; Research; Research Personnel; Resources; Sampling; Source; Testing; United States National Institutes of Health; Vaccinated; Vaccination; Vaccine Design; Vesicular stomatitis Indiana virus; Viral Load result; neurovirulence; nonhuman primate; prototype; simian human immunodeficiency virus; vector

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Prototype recombinant vesicular stomatitis virus (rVSV) vectors expressing HIV/SIV antigens have been shown to elicit robust immune responses in rhesus macaques, and effect a significant reduction in viral load and alter disease pathogenesis following challenge with the simian-human immunodeficiency virus SHIV89.6P. However, when tested in a stringent non-human primate neurovirulence model, the prototype rVSV vector appeared to be inadequately attenuated for use in humans. Seven animals previously vaccinated in 2005 with VSV on this project were given a second DNA vaccine on 3/27/06 (the first was given in Oct. 2005). Mucosal samples and blood draws were collected to monitor immune response through May 2006. In January 2006, nineteen animals previously vaccinated in 2005 with VSV on this project were given another vaccination in January 2006. Blood samples, body temperature and mucosal samples were collected to monitor immune response. Twelve of the animals were released from the project in March 2006. The remaining seven animals received a final vaccination on 6/26/06. Samples were collected through August 2006 after which the animals were released from the project. Additional studies are planned using onlu Mamu Ao1 + monkeys to insure a strong immune response.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 表达HIV/SIV抗原的原型重组水泡性口炎病毒（rVSV）载体已显示在恒河猴中引发强免疫应答，并且在用猴-人免疫缺陷病毒SHIV89.6P攻击后显著降低病毒载量并改变疾病发病机制。然而，当在严格的非人灵长类动物神经毒力模型中测试时，原型rVSV载体似乎不足以减毒用于人类。 2006年3月27日，对2005年在本项目中接种VSV的7头动物进行了第二次DNA疫苗接种（第一次接种于2005年10月）。 收集粘液样本和抽血，以监测免疫反应，直到2006年5月。 2006年1月，本项目中之前于2005年接种VSV的19头动物于2006年1月再次接种疫苗。 采集血液样本、体温和粘膜样本以监测免疫应答。 其中12只动物于2006年3月从该项目中释放。 其余7只动物于2006年6月26日接受最终疫苗接种。 采集样品至2006年8月，之后将动物从项目中释放。 计划使用onlu Mamu Ao 1+猴进行其他研究，以确保强烈的免疫应答。